Protalix BioTherapeutics (PLX)
Develops and manufactures plant-cell-derived enzyme therapies for rare diseases.
$2.80
vs last close−0.04 (−1.41%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 4 | 13 | 18 | 18 | 10 | 16 | 18 | 9 | 34 | 20 |
| Cost of revenue | 9 | 3 | 9 | 8 | 4 | 8 | 6 | 8 | 5 | 4 | 8 |
| Gross profit | 2 | 1 | 4 | 10 | 14 | 2 | 10 | 10 | 5 | 30 | 12 |
| 7 | 6 | 6 | 6 | 7 | 6 | 9 | 7 | 9 | 8 | 7 | |
| Research & development | 3 | 3 | 3 | 3 | 4 | 3 | 6 | 4 | 6 | 5 | 4 |
| 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −4 | 3 |
| Operating income | −6 | −5 | −2 | 4 | 7 | −4 | 1 | 2 | −5 | 21 | 5 |
| −1 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Interest expense | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | −1 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 |
| Income before tax | −6 | −5 | −2 | 4 | 7 | −4 | 1 | 2 | −5 | 21 | 5 |
| Income tax expense | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 3 | 1 |
| Net income from continuing operations | −6 | −5 | −2 | 3 | 6 | −4 | 0 | 2 | −6 | 18 | 4 |
| Net income | −6 | −5 | −2 | 3 | 6 | −4 | 0 | 2 | −6 | 18 | 4 |
| EPS, basic | −$0.08 | −$0.06 | −$0.03 | $0.04 | $0.09 | −$0.05 | $0.00 | $0.03 | −$0.07 | $0.23 | $0.05 |
| EPS, diluted | −$0.08 | −$0.06 | −$0.03 | $0.03 | $0.09 | −$0.05 | $0.00 | $0.03 | −$0.07 | $0.22 | $0.05 |
| Weighted average shares, basic | 73 | 73 | 73 | 74 | 74 | 77 | 79 | 79 | 79 | 80 | 80 |
| Weighted average shares, diluted | 73 | 73 | 73 | 81 | 81 | 77 | 81 | 81 | 79 | 83 | 83 |
| EBITDA | −5 | −4 | −2 | 4 | 8 | −3 | 2 | 3 | −4 | 22 | 6 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −6 | −4 | −2 | 4 | 7 | −4 | 1 | 2 | −4 | 21 | 5 |